期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 96, 期 4, 页码 429-437出版社
WILEY
DOI: 10.1038/clpt.2014.134
关键词
-
资金
- National Institute of Child Health and Human Development (NICHD) [HHSN201000003I, HHSN27500006]
- National Center for Advancing Translational Sciences of National Institutes of Health (NIH) [UL1TR001117]
Clindamycin is commonly prescribed to treat children with skin and skin-structure infections (including those caused by community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA)), yet little is known about its pharmacokinetics (PK) across pediatric age groups. A population PK analysis was performed in NONMEM using samples collected in an opportunistic study from children receiving i.v. clindamycin per standard of care. The final model was used to optimize pediatric dosing to match adult exposure proven effective against CA-MRSA. A total of 194 plasma PK samples collected from 125 children were included in the analysis. A one-compartment model described the data well. The final model included body weight and a sigmoidal maturation relationship between postmenstrual age (PMA) and clearance (CL):CL (l/h) = 13.7 x (weight/70)(0.75) x (PMA(3.1)/(43.6(3.1) + PMA(3.1))); V (l) = 61.8 x (weight/70). Maturation reached 50% of adult CL values at similar to 44 weeks PMA. Our findings support age-based dosing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据